beluuga.ai

Overview

TAUNS Laboratories,Inc.

Towns Co., Ltd. is a Japanese manufacturer of rapid antigen diagnostic test kits for infectious diseases, operating for over 30 years since its founding in 1987. The company's flagship product line, 'ImmunoAce®', utilizes proprietary immunochromatography technology—including a unique platinum-gold colloidal particle innovation that displays results as high-visibility black lines—to enable point-of-care testing for pathogens including influenza, SARS-CoV-2, adenovirus, RSV, hMPV, and others without specialized equipment. Products are distributed primarily in Japan through pharmaceutical wholesalers to hospitals, clinics, and research institutions, as well as internationally to organizations such as the WHO and bioventure companies.

Market Cap

¥53.1B

US$339M

¥64.7B

US$413M

Stock¥499▼-0.60%

US$1 = ¥156.80 (2026-10-23)

LTM EV/EBITDA

12.2

LTM EV/EBIT

15.4

LTM PER

9.7

LTM PBR

2.7

Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-31.7%pt

Oct 24, 25 – Oct 23, 26StockTOPIX

MC → EV Bridge

AI Briefing

Generating insights…

Performance & Balance

Revenue 5Y (¥B)

EBITDA 5Y (¥B)

Net Income 5Y (¥B)

Capital Structure

48%

52%

EquityD/E 1.09xDebt

Liquidity vs Debt 5Y (¥B)▼ Net Debt

CashInv. Sec.Debt

Shareholders

Top 10 hold 71.3%

as of 2026-06-30 · Source: Annual Securities Report

CITIC CAPITAL JAPAN PARTNERS III, L.P. (Standing Proxy: Daiwa Securities Co. Ltd.)

39.09%

Masaki NONAKA

29.27%

Nomura Trust and Banking Co., Ltd. (Investment Trust Account)

0.83%

Medical Concierge Co., Ltd.

0.65%

The Master Trust Bank of Japan, Ltd. (Trust Account)

0.32%

Koichiro SAKAMOTO

0.32%

CCJP III CO-INVESTMENT, L.P. (Standing Proxy: Daiwa Securities Co. Ltd.)

0.24%

Custody Bank of Japan, Ltd. (Trust Account)

0.20%

Tsuyoshi KURA

0.20%

Katashi YAMAMOTO

0.15%

Management

5 officers

Masaki NONAKA

Representative Director, President

Oct 1999 Joined Ohta Showa Audit Corporation (now EY ShinNihon LLC) Apr 2003 Joined The Japan Research Institute, Limited Sep 2005 Joined American Life Insurance Company, Japan Branch (now MetLife Insurance K.K.) Jun 2006 Joined Mizuho Capital Partners Co., Ltd. (now MCP Partners Co., Ltd.) Jul 2007 General Manager, Business Development Department and Director in charge of overseas business, the Company Apr 2014 Representative Director, President, the Company (current)

1975-06-11

Caroline F. BENTON

Director, Audit and Supervisory Committee Member

May 2008 Professor, Graduate School of Business Sciences, University of Tsukuba Apr 2013 Vice President, University of Tsukuba Apr 2015 Executive Director for International Affairs, University of Tsukuba Apr 2019 Member, Management Council, Nara Institute of Science and Technology Apr 2019 Trustee, TSUKUBA GLOBAL ACADEMY (current) Apr 2019 Member, Education and Research Council, Research Organization of Information and Systems (current) Oct 2020 Outside Audit & Supervisory Board Member, the Company Apr 2021 Member, Council for National Research and Development Agencies, Ministry of Education, Culture, Sports, Science and Technology (current) Dec 2021 Outside Director, Gakken Holdings Co., Ltd. (current) Apr 2023 Assistant to the President and Professor, Business Science Division, University of Tsukuba (current) Aug 2024 Supporter, Program for Promoting Regional Core and Distinctive Research Universities, Japan Society for the Promotion of Science (current) Apr 2025 Director (part-time), Nara Institute of Science and Technology (current) Sep 2026 Outside Director (Audit and Supervisory Committee Member), the Company (current)

1961-08-02

Satonori MISHINA

Director, Audit and Supervisory Committee Member

Apr 2008 Joined Eli Lilly Japan K.K. Mar 2013 Joined PricewaterhouseCoopers Co., Ltd. Mar 2015 Joined e-Solutions Co., Ltd. Apr 2016 Director, NC Medical Research Inc. Oct 2016 General Manager, Life Science Business Division, e-Solutions Co., Ltd. Apr 2020 Designated Member, Scines LLC (current) Sep 2020 Outside Director, the Company Mar 2023 Director and COO, Tokiwa Bio Co., Ltd. Jul 2026 Representative Director and CEO, Orinas Biosciences K.K. (current) Sep 2026 Outside Director (Audit and Supervisory Committee Member), the Company (current)

1983-03-24

Osamu CHIBA

Director, Audit and Supervisory Committee Member

Apr 1987 Joined Mitsubishi Corporation Oct 2004 Registered as attorney (Daini Tokyo Bar Association); joined Akebono Sogo Law Office Nov 2011 Supervisory Director, Kenedix Residential Next Investment Corporation (now KDX Realty Investment Corporation) Jan 2013 Partner Attorney, Akebono Sogo Law Office Jun 2016 Outside Audit & Supervisory Board Member, Maruzen Shokuhin Kogyo Co., Ltd. (current) Jun 2017 Outside Director (Audit and Supervisory Committee Member), IMAGICA GROUP Inc. Jan 2022 Representative Attorney, Akebono Sogo Law Office (current) Sep 2022 Outside Director, the Company Aug 2025 Supervisory Director, Kenedix Private Investment Corporation (current) Jun 2026 Audit & Supervisory Board Member, IMAGICA GROUP Inc. (current) Sep 2026 Outside Director (Audit and Supervisory Committee Member), the Company (current)

1963-10-24

Masahiro ITO

Director

Apr 1998 Joined Bain & Company Jun 2004 Seconded to Industrial Revitalization Corporation of Japan Nov 2006 Joined CITIC Capital Partners Japan Limited (now Trustar Capital Partners Japan Limited), Managing Director Apr 2016 Representative Director, the Company Jun 2017 Director, the Company (current) Sep 2019 Outside Director, MP Holdings Co., Ltd. (now Marukiri Sangyo Co., Ltd.) (current) Apr 2023 Senior Managing Director and Japan Representative, Trustar Capital Partners Japan Limited Nov 2023 Representative Director, KG Holdings Co., Ltd. Dec 2023 Outside Director, Kaneko Shoten Co., Ltd. Jan 2024 Partner and Japan Representative, Trustar Capital Partners Japan Limited (current) Nov 2024 Director, KG Holdings Co., Ltd. (current)

1973-07-11

Large Shareholding Reports

CJP III GP Ltd.

2026-10-19

41.92%→39.05%

CJP III GP Ltd.

2025-12-25

41.92%→39.20%

Correction filing (name/detail fix only) — ratio carried over from the original filing

CJP III GP Ltd.

2025-12-24

41.92%→39.20%

Masaki NONAKA

2025-12-19

29.63%→29.63%